Bordeaux, Boston, December 22, 2014: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants,
announced today its schedule for the publication of financial information for 2015.
Event Dates*
2014 Full-Year Sales January 7, 2015
2014 Full-Year Results March 31, 2015
2015 First-Quarter Sales April 28, 2015
Annual General Meeting June 17, 2015
2015 First-Half Sales July 28, 2015
2015 First-Half Results September 15, 2015
2015 Third-Quarter Sales October 27, 2015
Note (*): Press releases are published after market closes. Subject to modification.
About IMPLANET
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2013 sales of €6.7 million. For further information, please visit www.implanet.com.